NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundContinuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).ObjectiveTo assess the 6-month efficacy and tolerability of CSAI in MSA patients.MethodsFrench multicenter retrospective registry-based analysis of CSAI use in MSA. The primary outcome was the 6-month clinical response using the Clinical Global Impression Improvement (CGI-I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.ResultsFifty patients were included; 94% had MSA-P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% "much," 54% "minimally"), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.ConclusionIn selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short-term clinical benefit with acceptable tolerability.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.